Details of the Drug Combination

General Information of Drug Combination (ID: DCVQUGZ)

Drug Combination Name

SB 228357 T-3.5

Indication

Disease Entry	Status	REF
Hepatoblastoma	Investigative	[1]

Component Drugs

SB 228357 DMKA8R4

T-3.5 DM3Q1HL

Small molecular drug

N.A.

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: HB3

Zero Interaction Potency (ZIP) Score: 7.807

Bliss Independence Score: 9.199

Loewe Additivity Score: 0.016

LHighest Single Agent (HSA) Score: 1.381

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of SB 228357

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

SB 228357 Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[4]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[4]
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Antagonist	[4]
------------------------------------------------------------------------------------

Indication(s) of T-3.5

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Investigative	[3]

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 192).
3	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4	Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.